成人哮喘患者带状疱疹全球负担:系统综述与荟萃分析
该系统综述与荟萃分析纳入19项研究,评估成人哮喘患者带状疱疹(HZ)负担。≥18岁成人HZ合并发病率为5.71/1000人年,≥60岁为10.33/1000人年;哮喘患者发生HZ的合并率比为1.23(≥18岁)和1.36(≥50岁),且使用全身糖皮质激素等治疗者风险更高。哮喘还与带状疱疹后神经痛和眼部带状疱疹风险增加相关。
要点
- 成人哮喘患者HZ发病率随年龄升高,≥60岁达10.33/1000人年。
- 哮喘患者HZ风险增加,≥50岁人群率比1.36。
- 使用全身糖皮质激素等治疗者HZ风险更高,可考虑接种HZ疫苗。
核心结论
- 成人哮喘患者带状疱疹风险增加,老年人和使用口服糖皮质激素等特定治疗者风险更高。
- HZ疫苗可用于包括哮喘在内的合并症成人,可作为整合呼吸照护的一部分。
研究设计与样本
- 全球系统文献综述与荟萃分析,检索MEDLINE和Embase(2003-2024年)。
- 纳入19项关于成人(≥18岁)哮喘患者HZ结局(发病率、风险和并发症)的研究。
主要发现
- ≥18岁成人HZ合并发病率为5.71/1000人年(95%CI 4.68-6.96)。
- <60岁者HZ发病率为4.20/1000人年(95%CI 3.09-5.70),≥60岁者为10.33/1000人年(95%CI 9.17-11.64)。
- ≥18岁者发生HZ的合并率比为1.23(95%CI 1.11-1.35),≥50岁者为1.36(95%CI 1.15-1.61)。
- 使用全身糖皮质激素、长效β受体激动剂联合吸入糖皮质激素及「附加治疗」的哮喘患者HZ风险更高。
- 哮喘与带状疱疹后神经痛风险增加相关(OR 1.21,95%CI 1.06-1.37),与眼部带状疱疹风险增加相关(OR 1.9,95%CI 1.1-3.2)。
关键数值与推荐
- 成人哮喘患者HZ合并发病率5.71/1000人年(95%CI 4.68-6.96)。
- ≥60岁哮喘患者HZ发病率10.33/1000人年(95%CI 9.17-11.64)。
- ≥50岁哮喘患者HZ率比1.36(95%CI 1.15-1.61)。
- 带状疱疹后神经痛OR 1.21(95%CI 1.06-1.37),眼部带状疱疹OR 1.9(95%CI 1.1-3.2)。
临床怎么用
- 呼吸科医生应认识到成人哮喘患者,尤其老年和使用全身糖皮质激素者,HZ风险增加。
- 可考虑将HZ疫苗接种作为哮喘患者整合呼吸照护的一部分。
局限性
- 研究设计、设置、病例定义和随访时长的差异导致异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma is a common respiratory disease, which may be associated with an increased risk of herpes zoster (HZ), often a debilitating disease associated with severe pain. This is the first systematic review with the objective of summarising evidence on HZ burden in adults with asthma. METHODS: A global systematic literature review and meta-analysis was conducted (MEDLINE and Embase, 2003-2024) on HZ burden (incidence, risk and complications) in adults (≥18 years) with asthma. RESULTS: There were 19 studies included on HZ outcomes in adults with asthma. Pooled HZ incidence per 1000 person-years was 5.71 (95% CI 4.68-6.96) in adults aged ≥18 years (4.20 (95% CI 3.09-5.70) in those aged <60 years versus 10.33 (95% CI 9.17-11.64) in those aged ≥60 years). The pooled rate ratio for developing HZ was 1.23 (95% CI 1.11-1.35) in those aged ≥18 years and 1.36 (95% CI 1.15-1.61) in those aged ≥50 years. The risk of HZ was higher in people with asthma using systemic corticosteroids, long-acting β-agonists plus inhaled corticosteroids and "add-on therapy". Asthma was also associated with an increased risk of post-herpetic neuralgia (OR 1.21, 95% CI 1.06-1.37) and HZ ophthalmicus (OR 1.9, 95% CI 1.1-3.2). Differences in study design, setting, case definitions and follow-up durations led to heterogeneity. CONCLUSIONS: This systematic literature review and meta-analysis found that adults with asthma have an increased risk of HZ, with higher risks in older age groups and in those on certain treatments, such as oral corticosteroids. HZ vaccines are available for adults, including those with comorbidities such as asthma, and can be considered as part of integrated respiratory care.
引用
- Mortimer KJ, Cruz AA, Sepúlveda-Pachón IT, et al. Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis. Eur Respir J. 2024. PMID: 38901886. doi:10.1183/13993003.00462-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。